ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: A systemic review and meta-analysis

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1632-1640

  Yin, Ming ^a   Yan, Jingrong ^b   Martinez Balibrea, Eva ^d   Graziano, Francesco ^e   Lenz, Heinz Josef ^c   Kim, Hyo Jin ^f   Robert, Jacques ⁱ   Im, Seock Ah ^g   Wang, Wei Shu ^h   Etienne Grimaldi, Marie Christine ^j   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e SAN SALVATORE HOSPITAL   (Italy)

^f Dong A University College of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j CENTRE ANTOINE LACASSAGNE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYTOSINE; FLUOROURACIL; FOLINIC ACID; GUANINE; OXALIPLATIN; THYMINE;

ALLELE; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; ERCC1 GENE; ERCC2 GENE; ETHNIC DIFFERENCE; GENE; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ALLELES; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; STOMACH NEOPLASMS; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 79952728697     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2169     Document Type: Article

References (47)

1. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9. (Pubitemid 46630593)
3. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 Suppl 3:49-58. (Pubitemid 43153809)
4. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60. (Pubitemid 46196586)
5. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003;66:225-37. (Pubitemid 36776396)
6. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-2. (Pubitemid 41262934)
7. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555-60.
8. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000;21:551-5. (Pubitemid 30214005)
9. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-71. (Pubitemid 30265141)
10. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009;64:131-9.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
14. Lin DY, Sullivan PF. Meta-analysis of genome-wide association studies with overlapping subjects. Am J Hum Genet 2009;85:862-72.
15. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. (Pubitemid 36143396)
16. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007;15:1049-53. (Pubitemid 47491460)
17. Zarate R, Rodriguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010;102:987-94.
18. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci 2010;101:793-9.
19. Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007;72:364-70. (Pubitemid 351238151)
20. Paré L, Marcuello E, Altes A, del Río E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008;99:1050-5.
21. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009;100:278-83.
22. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148.
23. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000;89:160-6. (Pubitemid 30185925)
24. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 1987;84:5024-8. (Pubitemid 17095857)
25. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31. (Pubitemid 46810280)
26. Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993;4:491-500. (Pubitemid 23253708)
27. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902. (Pubitemid 34984411)
28. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 1992;52:1710-6.
29. Oye RK, Shapiro MF. Reporting results from chemotherapy trials. Does response make a difference in patient survival? JAMA 1984;252:2722-5.
30. Park D, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. ERCC1 polymorphism is associated with differential ERCC1 gene expression. In: ASCO Proceedings. San Francisco, CA: American Association for Cancer Research; 2002.
31. Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q. Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 2004;25:1695-700. (Pubitemid 39214312)
32. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-9. (Pubitemid 34224005)
33. Spindler KL, Andersen RF, Jensen LH, Ploen J, Jakobsen A. EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol 2010;21:535-9.
34. Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009;100:1261-6.
35. Liang J LH, Yao R, Liang H, Wu G. ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Chin-German J Clin Oncol 2008;7:455-9.
36. Seo BG, Kwon HC, Oh SY, Lee S, Kim SG, Kim SH, et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 2009;22:127-36.
37. Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, et al. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008;14:6401-7.
38. Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 2009;66:493-500.
39. Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 2007;8:1693-703.
40. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001;61:8654-8. (Pubitemid 34013872)
41. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009;101:998-1004.
42. Spindler KL, Andersen RF, Jensen LH, Ploen J, Jakobsen A. EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol ;21:535-9.
43. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7. (Pubitemid 41262950)
44. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-54. (Pubitemid 46640571)
45. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-54. (Pubitemid 39037082)
46. Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 2008;44:1229-37.
47. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010;69:58-66.